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Introduction: Decoy receptor 3 (DcR3), a soluble receptor belonging to the tumor necrosis factor (TNF)
receptor superfamily, competitively binds and inhibits the TNF family including Fas-ligand (Fas-L),
lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry
mediator on T-cells (LIGHT) and TNF-like ligand 1A (TL1A). In this study, we investigated the functions of
DcR3 on osteoarthritis (OA) chondrocytes.
Methods: Expressions of DcR3 in chondrocytes were measured by realtime Reverse Transcriptase-Poly-
merase Chain Reaction (RT-PCR). Expression of DcR3 in sera and joint ﬂuids was measured by enzyme-
linked immunosorbent assay (ELISA). Chondrocytes were incubated with DcR3-Fc chimera protein
(DcR3-Fc) before induction of apoptosis by Fas-L and apoptosis was detected with terminal deoxy-
nucleotidyl transferase (TdT)-mediated dUTP nick end labelling labeling (TUNEL) staining and Western
blotting of caspase 8 and poly (ADP-ribose) polymerase (PARP). Chondrocytes were incubated with
DcR3-Fc and the proliferation was analyzed by 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate (WST) assay. Phosphorylation of Extracellular Signal-Regulated Kinase (ERK),
P38 mitogen-activated protein kinase (MAPK) and Jun N-terminal Kinase (JNK) in chondrocytes was
measured by Western blotting after incubation with DcR3-Fc, Mitogen-activated protein kinase kinase
(MEK1/2) inhibitor, or P38 MAPK inhibitor. Chondrocytes were treated with DcR3-
Fc after pre-incubation with blocking antibody of Fas-L, LIGHT and TL1A, and proliferation or
phosphorylation of ERK was analyzed.
Results: DcR3 was expressed in OA and normal chondrocytes. DcR3-Fc protects chondrocytes from Fas-
induced apoptosis. DcR3-Fc increased chondrocytes proliferation and induced the phosphorylation of
ERK speciﬁcally. DcR3-induced chondrocytes proliferation was inhibited by pre-incubation of PD098059
or blocking Fas-L antibody. DcR3 increased chondrocytes proliferation in OA chondrocytes, but did not in
normal.
Conclusion: DcR3 regulates the proliferation of OA chondrocytes via ERK signaling and Fas-induced
apoptosis.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Decoy receptor 3 (DcR3)/TR6/M68 is a member of the tumor
necrosis factor receptor (TNFR) superfamily identiﬁed1. DcR3 lacks
the transmembrane domain of conventional TNFRs and is believed
to be a secreted protein1. DcR3 is expressed in some normal tissuesT. Nishiyama, Department of
te School of Medicine,
pan. Tel: 81-78-382-5985;
shiyama).
s Research Society International. Pincluding colon, stomach, spleen, lymph node, spinal cord,
pancreas, and lung1,2. DcR3 is overexpressed in tumor cells
including lung and colon cancers1, gliomas, and gastrointestinal
tract tumors2. Overexpression of DcR3 might beneﬁt tumors by
helping them to avoid the cytotoxic and regulatory effects of Fas-
ligand (Fas-L)1, lymphotoxin-like inducible protein that competes
with glycoprotein D for binding herpesvirus entry mediator on
T-cells (LIGHT)3, and TNF-like ligand 1A (TL1A)4. Furthermore,
DcR3 is expressed in synovial cells of both osteoarthritis (OA) and
rheumatoid arthritis (RA)5. Overexpressed DcR3 in rheumatoid
synovial cells stimulated with proinﬂammatory tumor necrosis
factor (TNF) alpha protects the cells from apoptosis5,6.ublished by Elsevier Ltd. All rights reserved.
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cartilage, is characterized by extracellular matrix damage and an
important loss in tissue cellularity7. Cartilage cells are mainly
responsible for the anabolicecatabolic balance required for matrix
maintenance and tissue function8. OA cartilage has a higher
proportion of apoptotic chondrocytes than normal cartilage9 and
apoptosis may play a role in diseases involving articular cartilage
degeneration10. Therefore, DcR3 might be involved in the regula-
tion of chondrocyte apoptosis.
Further, recently, DcR3 was reported to function as a ligand. The
expression of Human Leukocyte Antigen DR-1 (HLA-DR) and other
costimulatory molecules such as CD40, CD54/ICAM-1, CD1a and
CD80/B7.1 was down-regulated by DcR3-Fc and the costimulatory
molecule CD86/B7.2 was up-regulated in DCs11.
Hence, we speculated that DcR3 might be expressed in chon-
drocytes and regulate apoptosis and proliferation of chondrocytes
possibly resulting in cartilage regeneration. In this study, therefore,
we investigated DcR3 expression in chondrocytes and analyzed the
function of DcR3 in apoptosis and proliferation, and suggested that
DcR3 plays a substantial role in the physiology of OA chondrocytes.
Materials and methods
Preparation of cartilage
Cartilage tissues were obtained during total hip joint replace-
ment surgery from 19 patients with OA. Diagnosis of OA was based
on clinical, laboratory, and radiographic evaluations. Normal
cartilage tissues were obtained during surgery of femoral neck
fracture from seven patients with no history of joint disease and
with macroscopically normal cartilage. All the samples were
obtained in accordance with the World Medical Association
Declaration of Helsinki Ethical Principles for Medical Research
Involving Human Subjects.
Cell culture
Chondrocytes were isolated and cultured from cartilage tissues.
Tissues were minced and incubated with trypsin (0.5 mg/ml)
(Sigma, St. Louis, MO, USA) for 15 min at 37C, after which the
cartilage was treated with Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Gibco BR, Grand Island, NY, USA) containing 0.2% of
collagenase (Sigma) at 37C for 15 h. Dissociated cells were cultured
in DMEM supplemented with 10% fetal bovine serum (FBS; Bio-
whittaker, Walkersville, ML, USA) and 100 U/ml of pen-
icillinestreptomycin. After overnight culture, non-adherent cells
were removed, and adherent cells were further incubated in fresh
medium. All experiments were conducted using ﬁrst passage cells.
Quantiﬁcation of DcR3, Fas-L and Fas mRNA expression
Chondrocytes were cultured in 6-well plates with various
stimulations, and RNAwas extracted with QIAshredder and RNeasy
Mini kit (Qiagen, Hilden, Germany) according to themanufacturer’s
protocol. 1 mg of total RNA was reverse-transcribed to ﬁrst-strand
cDNAwith 1.25 mMoligo dT primer in 40 ml PCR buffer II containing
2.5 mMMgC12, 0.5 mMdNTPmix, 0.5 U RNase inhibitor, and 1.25 U
MuLV reverse transcriptase (Perkin Elmer, Foster City, CA, USA) at
42C for 60 min.
The relative expression levels of mRNA encoding DcR3, Fas-L or
Fas in chondrocytes were analyzed by TaqMan realtime PCR using
an ABI prism 7500 sequence detection system (Applied Biosystems,
Foster City, CA, USA). Pre-designed primers and probes for human
DcR3, Fas-L, Fas and human glyceraldehyde-3-phosphatedehydrogenase (GAPDH) to be used as the control were obtained
from Applied Biosystems.
Quantiﬁcation of DcR3 protein concentration in sera or joint ﬂuid
In order to measure DcR3 in serum and joint ﬂuid, we used the
human DcR3 enzyme-linked immunosorbent assay (ELISA) kit
(Bender Med Systems, Vienna, Austria) according to the manufac-
turer’s protocol. Brieﬂy, 100 ml of each sample were incubated in
duplicate in microplates coated with anti-DcR3 monoclonal anti-
body for 2 h. Following incubation, biotin-conjugate anti-DcR3
monoclonal antibody was added and incubated as a primary anti-
body for 2 h. After the microplate had been washed, streptavidin-
horseradish peroxidase (HRP) was added and incubated for 1 h.
After washing off any unbound streptavidin-HRP, tetrame-
thylbenzidine was added as a substrate and the absorbance was
measured at 450 nm after 20 min in a microplate reader (BioTek
Instruments, Burlington, VT, USA). The absorbance of each sample
was plotted against a standard curve produced by serial dilutions of
recombinant human DcR3-Fc in duplicate. The concentrations of
DcR3 in serum and joint ﬂuid were calculated by logarithmic
analysis. All samples with an absorbance of less than zero according
to the standard curve were discarded from the ﬁnal analysis.
Fas-induced apoptosis in chondrocytes
Before the induction of apoptosis, chondrocytes were pre-
treated with 0.1, 1, 10 and 100 ng/ml of recombinant human DcR3-
Fc chimera protein (DcR3-Fc) (R&D Systems) for 24 h in Opti
Minimum essential medium (MEM) (Invitrogen, Carlsbad, CA, USA).
DcR3-Fc and recombinant DcR3 protein (rDcR3) have the same
binding afﬁnity to LIGHT and the same inhibitory effect on the
development of Cytotoxic T-lymphocyte (CTL) in mice indicating
that the biological effect of DcR3-Fc is equivalent to rDcR312.
Fas-induced apoptosis was introduced by incubation with
100 ng/ml of recombinant human Fas-ligand (hFas-L) (R&D
Systems) for an additional 12 h. Fas-induced apoptotic signals were
conﬁrmed by terminal deoxynucleotidyl transferase (TdT)-medi-
ated dUTP nick end labeling (TUNEL) staining and the detection of
cleavage of caspase 813 and poly (ADP-ribose) polymerase (PARP)9.
Proliferation assay
Chondrocytes were seeded in 96-well plates at a density of
5103 cells per well in DMEM medium supplemented with 10%
FBS. After plating cells for overnight, chondrocytes were treated
with DcR3-Fc or IgG-Fc (Millipore, Billerica, MA, USA) as control to
eliminate the effects of Fc. In some cases, chondrocytes were pre-
incubated with blocking antibody of Fas-L (BD Pharmingen, San
Jose, CA, USA), LIGHT and TL1A (Biolegend, San Diego, CA, USA) or
IgG (Acris, Littleton, CO, USA) as control for 12 h. Cell proliferation
was assessed using Cell-Counting Kit-8 (Dojindo, Kumamoto,
Japan) (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate (WST) assay) according to the manufac-
turer’s instruction. The principle of WST assay is following.
Tetrazolium salt-8 (WST-8) is cleaved to soluble formazan dye by
the succinate-tetrazolium reductase, which exists in mitochondrial
respiratory chain and is active only in viable cells. Total activity of
this mitochondrial succinate-tetrazolium reductase in a sample
rises with the increase of viable cells. The absorbance of formazan
dye solution is in direct proportion to the number of viable cells.
Therefore, this assay is designed for non-radioactive quantiﬁcation
of cell growth and viability in proliferation. The values, corre-
sponding to the number of viable cells, were read at OD 450 nm
with Microplate Reader (BioTek Instrument, Winooski, VT, USA).
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Western blotting
Chondrocytes were washed three times with Phosphate
Buffered Saline (PBS) and lysed in hypotonic lysis buffer (25 mM
Tris, 1% NP-40, 150 mM NaCl, 1.5 mM Ethylene glycol tetraacetic
acid (EGTA)) supplemented with protease and phosphatase inhib-
itor mix (Roche Diagnostics, Basel, Switzerland) on ice for 20 min.
The lysates were centrifuged at 15,000 rpm for 20 min to remove
cellular debris and the supernatants were collected. Cytoplasmic
proteins were quantiﬁed by the Bradford method with protein
assay reagent (BioRad, Hercules, CA, USA), and diluted to an equal
concentration with hypotonic buffer. Each sample was mixed with
3 electrophoresis sample buffer (BioRad) and electrophoresed on
7.5e15% polyacrylamide gradient gel (Biocraft, Tokyo, Japan) and
transblotted electrically onto the blotting membrane (GE Health-
care, Connecticut, CT, USA).
The expression of DcR3 protein was detected using rabbit anti-
human DcR3 polyclonal Ab (R&D systems). The expression of cas-
pase 8was detected usingmouse anti-human caspase 8monoclonal
Ab (Cell Signaling Technology, Beverly, MA, USA). The expression of
PARP was detected using rabbit anti-human PARP polyclonal Ab
(Cell Signaling Technology). The expression of phospho-Extracel-
lular Signal-Regulated Kinase (ERK) or ERK was detected using
mouse anti-human phospho-ERK Ab (Cell Signaling Technology) or
rabbit anti-human ERK Ab (Cell Signaling Technology). TheFig. 1. (a) Expression levels of DcR3, Fas-L or Fas mRNAwere quantiﬁed by realtime PCR. Exp
Columns represent mean values with 95% CI. The results shown are the average of seven in
joint ﬂuid levels of DcR3 protein were measured by ELISA. Control sera was collected from
represent mean values with 95% CI.expression of phospho-P38 mitogen-activated protein kinase
(MAPK) or P38 MAPK was detected using rabbit anti-human phos-
pho-P38MAPKAb (Cell Signaling Technology) or rabbit anti-human
P38 MAPK Ab (Cell Signaling Technology). The expression of phos-
pho-Jun N-terminal Kinase (JNK) or JNK was detected using rabbit
anti-human phospho-JNK Ab (Cell Signaling Technology) or rabbit
anti-human JNK Ab (Cell Signaling Technology).
HRP conjugated goat anti-rabbit IgG Ab (GE healthcare) or HRP
conjugated rabbit anti-mouse IgG Ab (GE healthcare) was used for
a secondary antibody, and the signals were visualized by ECL plus
reagent (GE healthcare) with Chemilumino analyzer LAS-3000 mini
(FUJI FILM, Tokyo, Japan). The expression of proteinswas determined
by semi-quantiﬁcation of digitally captured image using the public
domainNIH Imageprogram(developedat theU.S.National Institutes
of Health and available on the Internet at http://rsb.info.nih.gov/nih-
image/). Values were normalized to alpha-tublin expression.
TUNEL staining
2105 chondrocytes were cultured in 8-well chamber slides
(Nunc Roskilde, Denmark). After various stimulations, the chon-
drocytes were ﬁxed with 4% neutral buffered formalin for 10 min
and apoptotic cells were determined using TUNEL assay kit (Wako)
according to the manufacturer’s protocol.
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance, with Tukey’s post hoc test for multiple comparisons of
paired samples. Results are presented as mean values with 95%ression ratios of DcR3, Fas or Fas-L (OA chondrocytes/Normal chondrocytes) are shown.
dividual samples. Values were normalized to GAPDH expression. (b) Human Serum or
10 healthy subjects, OA sera and joint ﬂuid were from 10 subjects with OA. Columns
Fig. 2. (a and b) Effect of hFas-L and DcR3-Fc protein for Fas-induced apoptosis of chondrocytes. (a) Columns represent mean values with 95% CI. Columns represent of TUNEL
positive cells, at least 300 cells were counted by a blinded observer in the same experiment. The results shown are the average of four individual samples. (b) Expressions of cleaved
caspase 8 and PARP were analyzed by Western blotting. The results shown represent three independent experiments.
S. Hayashi et al. / Osteoarthritis and Cartilage 19 (2011) 903e910906conﬁdence intervals (95% CI), and were considered statistically
signiﬁcant for P< 0.05.
Results
Expression levels of DcR3 mRNA were not changed between OA and
normal chondrocytes
In order to compare the expression levels of DcR3, Fas-L or Fas
mRNA between OA and normal chondrocytes, we analyzed mRNA
levels by realtime Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR). The expression levels of DcR3 were not signiﬁ-
cantly changed between OA (mean¼ 0.89, 95% CI¼ 0.50e1.28,
N¼ 7) and normal chondrocytes (mean¼ 1, 95% CI¼ 0.78e1.22,
N¼ 7). The expression levels of Fas were not signiﬁcantly changedFig. 3. (a) Effect of DcR3 on chondrocyte proliferation analyzed by WST assay. Chondrocytes
the ratio of OD 450 nm value in comparisonwith untreated chondrocytes. The results shown
(b) Effect of DcR3-Fc for ERK, P38 MAPK, or JNK phosphorylation analyzed by Western blotti
10 and 30 min. The results shown represent three independent experiments.between OA (mean¼ 0.924, 95% CI¼ 0.56e1.29, N¼ 7) and normal
chondrocytes (mean¼ 1, 95% CI¼ 0.78e1.22, N¼ 7). However, the
levels of Fas-L were signiﬁcantly higher in OA (mean¼ 2.97, 95%
CI¼ 2.14e3.79, N¼ 7) than in normal chondrocytes (mean¼ 1, 95%
CI¼ 0.76e1.24, N¼ 7) (Fig. 1a).
DcR3 is expressed in joint ﬂuids of patients with OA
In order to analyze the expression of DcR3 protein in sera and
joint ﬂuid, we quantiﬁed the concentration of DcR3 by DcR3 ELISA
kit. The average concentration of serum DcR3 was 0.33 ng/ml in OA
patients (95% CI¼ 0.04e0.62, N¼ 10), and 0.24 ng/ml in healthy
donor (95% CI¼ 0.03e0.45, N¼ 10) (Fig. 1b). There was no signiﬁ-
cant difference between OA and healthy subjects. While, the
average concentration of DcR3 in joint ﬂuid of OA patients waswere incubated with 5 mg/ml of IgG-Fc or 1, 5 mg/ml of DcR3-Fc for 48 h. Columns show
are the average of four individual samples. Columns represent mean values with 95% CI.
ng. Chondrocytes were incubated with 5 mg/ml of DcR3-Fc or 5 mg/ml of IgG-Fc for 0, 5,
Fig. 4. Effects of PD098059 (PD) and SB203580 (SB) against DcR3-induced proliferation of chondrocytes. (a) Chondrocyte proliferation was analyzed by WST assay. Chondrocytes
were incubated with 5 mg/ml of IgG-Fc, 5 mg/ml of DcR3-Fc, 50 mM of PD098059 (R&D) or 10 mM of SB203580 (R&D) for 48 h. In some cases, chondrocytes were pre-treated with
50 mM of PD098059 or 10 mM of SB203580 for 30 min, and incubated with 5 mg/ml of DcR3-Fc for 48 h. Columns show the ratio of OD 450 nm value in comparison with untreated
chondrocytes. The results shown are the average of three individual samples. Columns represent mean values with 95% CI. (b) Phosphorylation of ERK was analyzed by Western
blotting. Chondrocytes were incubated with 5 mg/ml of IgG-Fc, 5 mg/ml of DcR3-Fc, 50 mM of PD098059 or 10 mM of SB203580 for 10 min. In some cases, chondrocytes were pre-
treated with 50 mM of PD098059 or 10 mM of SB203580 for 30 min, and incubated with 5 mg/ml of DcR3-Fc for 10 min. The results shown represent three independent experiments.
Fig. 5. Effects of blocking antibody of Fas-L, LIGHT and TL1A for DcR3-induced chondrocytes proliferation. (a) Chondrocyte proliferation was analyzed by WST assay. Chondrocytes
were pre-incubated with 100 ng/ml of blocking antibody of Fas-L, 5 mg/ml of blocking antibody of LIGHT and TL1A or 5 mg/ml of IgG as control for 12 h. After washing cells with PBS,
chondrocytes were incubated with 5 mg/ml of DcR3-Fc for 48 h. Columns show the ratio of OD 450 nm value in comparisonwith 5 mg/ml of IgG pre-treatment. The results shown are
the average of four individual samples. Columns represent mean values with 95% CI. (b) Phosphorylation of ERK was analyzed by Western blotting. After pre-incubation with IgG,
blocking antibody of Fas-L, LIGHT and TL1A for 12 h, chondrocytes were washed with PBS and incubated with 5 mg/ml of DcR3-Fc for 0, 5, 10 and 30 min.
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of DcR3 in joint ﬂuid of OA patients was much higher than in sera
(Fig. 1b).
DcR3 protein inhibited Fas-induced apoptosis in chondrocytes
TUNEL positive apoptotic cells induced by Fas-L were
signiﬁcantly decreased in a dose dependent manner when
chondrocytes were pre-incubated with DcR3-Fc protein
(Untreated: mean¼ 8, 95% CI¼ 5.7e10.3, N¼ 4) (0 ng/ml DcR3-
Fc: mean¼ 44.6, 95% CI¼ 35.5e53.8, N¼ 4) (0.1 ng/ml DcR3-Fc:
mean¼ 34.9, 95% CI¼ 31.8e38.1, N¼ 4) (1 ng/ml DcR3-
Fc: mean¼ 30.2, 95% CI¼ 28.0e32.4, N¼ 4) (10 ng/ml DcR3-Fc:
mean¼ 24.3, 95% CI¼ 17.8e30.7, N¼ 4) (100 ng/ml DcR3-
Fc: mean¼ 13.9, 95% CI¼ 5.7e22.1, N¼ 4) (Fig. 2a). The cleavage
of caspase 8 and PARP was increased by 100 ng/ml of Fas-L
treatment. However, the cleavage of caspase 8 and PARP with Fas-L
treatment was inhibited by pre-treatment with 100 ng/ml of
DcR3-Fc (Fig. 2b).
DcR3 increased OA chondrocytes proliferation via ERK
phosphorylation
WST assay revealed that chondrocytes proliferation were
increased by the treatment of DcR3-Fc in a dose dependent manner
(Untreated: mean¼ 1, 95% CI¼ 0.94e1.07, N¼ 4) (IgG-Fc:
mean¼ 1.04, 95% CI¼ 0.86e1.22, N¼ 4) (1 mg/ml DcR3-
Fc: mean¼ 1.20, 95% CI¼ 1.11e1.30, N¼ 4) (5 mg/ml DcR3-Fc:
mean¼ 1.32, 95% CI¼ 1.24e1.39, N¼ 4) (Fig. 3a).
In order to investigate the signal transduction of DcR3, we tested
phosphorylation of ERK, P38 MAPK and JNK in chondrocytes with
the treatment of 5 mg/ml of DcR3-Fc.
Western blotting revealed that phosphorylation of ERK was
increased to 12.63 folds of untreated samples at 10 min and 3.12
folds at 30 min by treatment with 5 mg/ml of DcR3-Fc (Fig. 3b).
While, neither P38 MAPK nor JNK signaling was activated by
treatment with 5 mg/ml of DcR3-Fc for up to 30 min (Fig. 3b).
Suppression of ERK activity inhibited DcR3-induced chondrocytes
proliferation
WST assay revealed that the effect of DcR3-Fc for chondrocytes
proliferation was inhibited by treatment with speciﬁc Mitogen-Fig. 6. Comparison of DcR3 effect on proliferation between OA and normal chondrocytes. C
proliferation was analyzed by WST assay. Columns show the ratio of OD 450 nm value in
panels: OA chondrocytes. The results shown are the average of four individual samples. Coactivated protein kinase kinase (MEK1/2) inhibitor PD098059, but
not by speciﬁc P38MAPK inhibitor SB203580 (Untreated: mean¼ 1,
95% CI¼ 0.91e1.09, N¼ 3) (IgG-Fc: mean¼ 1.01, 95% CI¼ 0.93e1.10,
N¼ 3) (PD: mean¼ 0.96, 95% CI¼ 0.90e1.02, N¼ 3) (SB:
mean¼ 1.04, 95% CI¼ 0.99e1.09, N¼ 3) (DcR3-Fc: mean¼ 1.36,
95% CI¼ 1.16e1.60, N¼ 3) (DcR3-Fcþ PD: mean¼ 1.10, 95%
CI¼ 0.94e1.26, N¼ 3) (DcR3-Fcþ SB: mean¼ 1.31, 95%
CI¼ 1.22e1.41, N¼ 3) (Fig. 4a). Western blotting conﬁrmed that the
activation of ERK signaling by treatment with 5 mg/ml DcR3-Fc was
inhibited by PD098059, but not by SB203580 (Fig. 4b).Anti-Fas-L antibody inhibited the DcR3-induced chondrocytes
proliferation through ERK signaling
In order to ﬁgure out the mechanism of DcR3-induced signal
transduction in chondrocytes proliferation, we tested the effect of
blocking antibody of Fas-L, LIGHT and TL1A for DcR3-induced
proliferation. WST assay revealed that the effect of DcR3-Fc for
chondrocytes proliferation was inhibited by pre-incubation with
blocking antibody of Fas-L, but not by blocking antibody of LIGHTor
TL1A (IgG: mean¼ 1, 95% CI¼ 0.98e1.02, N¼ 4) (Fas-L:
mean¼ 0.61, 95% CI¼ 0.56e0.67, N¼ 4) (LIGHT: mean¼ 1.03, 95%
CI¼ 0.71e1.36, N¼ 4) (TL1A: mean¼ 0.99, 95% CI¼ 0.98e1.02,
N¼ 4) (Fig. 5a). Western blotting showed that phosphorylation of
ERK by treatment with 5 mg/ml of DcR3-Fc was inhibited by pre-
incubation with blocking antibody of Fas-L, but not with blocking
antibody of LIGHT or TL1A (Fig. 5b).DcR3 did not increase proliferation of normal chondrocytes
In order to compare the difference between OA and normal
chondrocytes in response to DcR3 treatment, we tested chon-
drocytes proliferation by treatment of 5 mg/ml of DcR3-Fc in OA and
normal chondrocytes. WST assay revealed that DcR3-Fc increased
chondrocytes proliferation in OA chondrocytes, but did not in
normal (Untreated normal: mean¼ 1, 95% CI¼ 0.87e1.13, N¼ 4)
(Untreated OA: mean¼ 1, 95% CI¼ 0.82e1.18, N¼ 4) (IgG-Fc
normal: mean¼ 0.95, 95% CI¼ 0.88e1.02, N¼ 4) (IgG-Fc OA:
mean¼ 1.03, 95% CI¼ 0.94e1.12, N¼ 4) (DcR3-Fc normal:
mean¼ 1.09, 95% CI¼ 0.88e1.30, N¼ 4) (DcR3-Fc OA: mean¼ 1.31,
95% CI¼ 1.27e1.34, N¼ 4) (Fig. 6).hondrocytes were incubated with 5 mg/ml of IgG-Fc or DcR3-Fc for 48 h. Chondrocytes
comparison with untreated chondrocytes. White panels: Normal chondrocytes. Black
lumns represent mean values with 95% CI.
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A signiﬁcant body of knowledge about the mechanism of
chondrocytes apoptosis was reported. Many manuscripts reported
that chondrocytes apoptosis were induced via mitochondrial
pathway or cytokines like TNF alpha14,15. We also have shown that
mechanical stress induced chondrocytes apoptosis via p53-mito-
chondrial pathway14.
While, it has been reported that several stimuli including Fas-L16
induced apoptosis in chondrocytes and a signiﬁcant amount of Fas-
L was found in synovial ﬂuids from patients with OA16. Expression
of Fas-Lwas higher in aged cartilage than inmature cartilage, which
correlated with the decrease in viable cell density in rabbit articular
cartilage during aging17. We conﬁrmed that the expression of Fas-L
was increased in OA chondrocytes. These ﬁndings suggest that Fas/
Fas-L is an important molecule for the regulation of apoptosis of
chondrocytes in OA cartilage.
DcR3 is expressed in a variety of tissues and tumors1,2, and
regulates cell proliferation, however, the expression of DcR3 in
chondrocytes was not investigated previously. In this study, we
demonstrated that DcR3 is expressed in normal and OA chon-
drocytes similarly, and the expression levels of DcR3 protein in the
joint ﬂuid were higher than in sera. Average concentration of DcR3
in joint ﬂuid of OA patients was 1.44 ng/ml. While, we also
demonstrated that 1 ng/ml of DcR3-Fc inhibited Fas-induced
apoptosis in chondrocytes. These results suggest that DcR3 protein
is secreted into the joint and actually protects chondrocytes from
death via Fas-induced apoptosis in physiological circumstance.
However, the amount of DcR3 may be insufﬁcient to bind to the
increased amount of Fas-L in OA cartilage16,17 and incapable to
inhibit Fas-induced apoptosis.
From the standpoint of chondrocyte proliferation, MAPK
signaling is one of the essential mitogenic signaling in many kinds
of cells and plays a key role in a variety of cellular responses
including proliferation, differentiation and apoptosis of cells18,19.
We recently demonstrated that DcR3 has functions as a ligand to
inhibit apoptosis in THP-1 macrophages by increasing very late
antigen 4 (VLA4) expression20. Several studies have reported that
soluble DcR3 activates reverse signaling as a ligand, inducing
osteoclast formation from monocytes/macrophages via ERK and
p38 MAPK signaling21, inducing actin reorganization and
enhancing adhesion of monocytes22, and inducing dendritic cell
apoptosis by activating Protein Kinase C (PKC-d) and JNK23,24. In this
study we demonstrated that DcR3-Fc increased proliferation of
chondrocytes through activation of ERK signaling pathway specif-
ically, but not in p38 MAPK or JNK.
DcR3-Fc fusion protein has been shown to have similar binding
afﬁnity and speciﬁcity as DcR325,26, and in our experiments control
IgG-Fc had no effect on chondrocytes. Our results therefore are the
ﬁrst to suggest that DcR3 may regulate chondrocytes proliferation
by binding Fas-L through ERK signaling. We further demonstrated
that chondrocytes proliferation by DcR3-Fc treatment was different
between OA and normal chondrocytes. The difference of prolifer-
ation might be dependent on the difference of Fas-L expression
between OA and normal chondrocytes.
In conclusion, DcR3 regulated chondrocytes proliferation via
ERK signaling and Fas-induced apoptosis. These ﬁndings suggest
that analysis of DcR3 function could be one of therapeutic strategies
for OA treatment.
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